BillionToOne

BillionToOne is ranked at the top 5% of Y Combinator companies with close to $400M in funding. In June 2024, we closed a $130M Series D resulting in a company valuation of over $1 billion. We have developed a DNA molecular counter that increases cfDNA diagnostic resolution by over 1,000x. Our first product, Unity, is the first and only non-invasive prenatal test that can directly screen an unborn baby and assess its risk for common and severe recessive gene disorders, chromosomal abnormalities, fetal sex, and fetal antigens from a single tube of blood from the pregnant mother.